Rescheduling Won't Fix Cannabis Industry Without Insurance Access

President Trump's executive order on cannabis rescheduling addresses tax burdens but misses a critical infrastructure gap—medical cannabis still can't access insurance reimbursement systems that sustain every other therapeutic industry.

Gennaro Luce and Matthew Myro Rothman of CannaLnx argue that while rescheduling would eliminate 280E tax penalties, the industry's real stabilization requires integration into healthcare payment systems. Without insurance coverage, medical cannabis remains a cash-only market disconnected from the infrastructure that governs prescription drugs, medical devices, and other therapeutic products.

"A stable cannabis industry requires more than tax normalization," the authors write. "It requires integration into healthcare infrastructure that governs how therapeutic products are accessed, financed and sustained."

The Insurance Problem

The disconnect creates a fundamental barrier for patients and providers. While pharmaceutical companies negotiate with insurers and Medicare, cannabis businesses operate entirely outside these systems. Patients pay out-of-pocket even when using cannabis for FDA-recognized conditions—a model that doesn't exist for any other prescribed therapeutic.

This payment structure limits market growth in ways tax reform alone can't solve. Insurance reimbursement drives adoption of medical treatments through reduced patient costs and physician confidence in prescribing. Cannabis lacks both mechanisms.

The authors point to momentum around federal reform following Trump's directive, with investors responding to potential rescheduling. But they warn this optimism overlooks structural issues that keep cannabis separate from mainstream healthcare economics.

Beyond 280E Relief

Rescheduling from Schedule I to Schedule III would let cannabis businesses deduct normal operating expenses, ending the 280E tax code's punishing treatment of the industry. Companies currently pay effective tax rates exceeding 70% because they can't deduct rent, payroll, or other standard costs.

Yet this tax normalization doesn't address why doctors remain hesitant to recommend cannabis or why patients struggle with affordability. Insurance coverage would change both dynamics—reducing patient costs through copays while giving physicians the reimbursement framework they use for every other treatment decision.

The healthcare integration gap also affects research and clinical acceptance. Pharmaceutical products gain legitimacy through insurance formularies and reimbursement codes. Cannabis products, regardless of schedule, remain outside this validation system.

What's Next

The op-ed suggests federal reform efforts should prioritize insurance access alongside scheduling changes. This means addressing regulatory barriers that prevent insurers from covering cannabis, creating reimbursement codes for cannabis products, and establishing clinical guidelines that insurers require for coverage decisions.

Some state-legal markets have begun exploring insurance models, but federal prohibition has blocked systematic integration. Rescheduling might remove some barriers, but it doesn't automatically grant insurance access—that requires separate policy changes at FDA, CMS, and insurance regulatory levels.

For the cannabis industry to achieve genuine stability, the authors argue, it needs the same financial infrastructure that supports every other medical product. Tax relief helps businesses survive. Insurance integration would let them actually thrive as healthcare providers.

The timeline for insurance reform remains unclear, even as rescheduling momentum builds. But the industry's long-term viability may depend more on payment system access than on tax code changes.

This article is based on original reporting by www.marijuanamoment.net.